1. Non-invasive blood glucose meter
In 2019, they signed a contract with the overseas company DIOS Pharma + ASUS, publicized that they could produce and sell a non-invasive blood glucose meter, then it fizzled out.
2. COVID vaccine 300 billion won contract
In 2021, they claimed the COVID vaccine trial showed good efficacy and that a 300 billion won contract was in progress, but after 7 disclosure corrections it was halted.
3. Oral insulin 200 billion won contract
They claimed they had proven the efficacy of oral insulin and announced a 200 billion won contract with the country's Donghwa Ilbo, but after 13 disclosure corrections over a full 3 years, it was halted.
Now, 5 years later, they have filed for Phase 1/2. But to do it properly it should be the US FDA, yet it is being conducted in Europe. The company claims a 10 percent chance of success, however
the chance of success is almost nonexistent.
4. S-pass
It has no patent, and they used the exaggerated expression "successful patent circumvention," which became controversial. They have never demonstrated the technology, and
the claim that the technology has been proven is a one-sided assertion by the company.
5. Japanese obesity treatment 4 trillion won contract, sales after 6 years
Contract termination is very easy and the contract details are undisclosed. The counterparty said it was a strategically untreated business, which became controversial.
6. European obesity treatment 5.3 trillion won contract, sales after 6 years
The number of signing countries is 11 but only 10 were listed, for which they were criticized, and the contract amount is said to be 50.8 billion won, but the company was criticized by the exchange for calculating it by estimating future sales.
It became controversial because they calculated future sales of 5.3 trillion won by selling from 2033, 6 years later, until 2043. Such a calculation has reportedly never been seen even in the industry.
They were again criticized because the counterparty was undisclosed and the contract details were undisclosed.
For Japan they were criticized for disclosing, and for Europe they were criticized for not disclosing. There are also suspicions of false disclosure.
In the history of stocks, there has never been a contract to sell something 6 years later that hasn't even been made. Samchundang has done it twice.
7. Eye drops 7.5 million units
They said they signed a contract with a European company via news rather than a disclosure, but 7.5 million units would be trillions of won, so it is subject to disclosure.
There are no contract details and no contract period. There is no reason for a confidentiality clause here. Yet it was not recorded in the subsequent business report. Is it news for stock hype??
8. The major shareholder posted a shareholder letter on the website saying the company's weight class is changing, and made a disclosure of a planned stake sale worth 250 billion won.
The tax is 100 billion won.. If the weight class goes up, shouldn't they just sell when it's higher? There is suspicious public opinion.
9. They say they are working on oral versions of the blockbusters Keytruda and Opdivo.
So Keytruda, Opdivo, obesity treatment, insulin, etc.
So one PhD is doing it with research funding of a few billion to a few hundred billion won
which means doing alone what thousands of PhDs failed at with hundreds of billions to trillions of won, which makes no sense.
Even concentrating on just one is questionable
and succeeding at even just one of these would be Nobel Prize material.
10. Eylea Vegzelma-free
They claim that by succeeding at just one biosimilar they will earn hundreds of billions of won with it, but there are 8 companies that have succeeded with this biosimilar, and it isn't such great technology that even companies with a market cap under 1 trillion won could succeed.
Even before Samsung's drug pricing, domestic sales were only 200-300 million won, and now that Samsung has cut to the lowest price, the competitiveness is gone. They couldn't even get US FDA approval, so they are also the slowest to enter the largest overseas market.
11. Complete absence of brokerage reports
Other than 4 reports by Wi Hae-ju of Korea Investment & Securities, there are no reports. If it's the No. 1 market cap, several should appear, but there are none at all. This is because the securities industry already sees it as a manipulation stock. The pharmaceutical industry has also continuously raised suspicions.
Wi Hae-ju should also be investigated. They entice with claims that 770 billion won in operating profit will come later, but they create an escape route by attaching the conditional "if realized." The conclusion is the "if it doesn't work out, never mind" approach.
12. Manipulation stock pattern
A stock that was rising gently suddenly floods out positive news, surges sharply, brings in nonsensical material, and the major shareholder sells. That is exactly Samchundang.
It is generally common for positive news to drive a rise singly, but rising like this with multiple ones is also very rare.
===
I hear Samchundang Pharmaceutical is going to sue that blog.
It will be revealed soon.
